Global Immune Check Point Inhibitors Market Size, Status and Forecast 2019-2025

Published On: Jun 2019

Format: PDF

Publisher: QY Research

Pages: 90

Report ID: 1875

Check point inhibitors are molecules that use the cosmic potential of the immune response system of the body, and its limitless influences to attack the cancer cells present inside the body, as well as avoids relapse of cancer cells. In case any relapse occurs in the body, it can easily be recognized and eliminated by the use of immune memory cells, leaving a healthy tissue.
Factors such as rise in incidences of cancer and high rate of associated mortality, increased healthcare expenditures, growth in government initiatives to alleviate cancer, and rise in public awareness boost the growth of immune checkpoint inhibitors market.
In 2018, the global Immune Check Point Inhibitors market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Immune Check Point Inhibitors status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Immune Check Point Inhibitors development in United States, Europe and China.

The key players covered in this study
Bristol-Myers Squibb Company
AstraZeneca plc
Merck & Co
Pfizer, Inc
F. Hoffmann-La Roche Ltd
Incyte Corporation
NewLink Genetics Corporation
Celldex Therapeutics, Inc
GlaxoSmithKline plc
Seattle Genetics, Inc.

Market segment by Type, the product can be split into
CLTA-4 Inhibitors
PD-1 & PD-L1 Inhibitor

Market segment by Application, split into
Lung Cancer
Blood Cancer
Renal Cancer
Bladder Cancer
Melanoma
Hodgkin Lymphoma

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Immune Check Point Inhibitors status, future forecast, growth opportunity, key market and key players.
To present the Immune Check Point Inhibitors development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Immune Check Point Inhibitors are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Immune Check Point Inhibitors Market Size Growth Rate by Type (2014-2025)
1.4.2 CLTA-4 Inhibitors
1.4.3 PD-1 & PD-L1 Inhibitor
1.5 Market by Application
1.5.1 Global Immune Check Point Inhibitors Market Share by Application (2014-2025)
1.5.2 Lung Cancer
1.5.3 Blood Cancer
1.5.4 Renal Cancer
1.5.5 Bladder Cancer
1.5.6 Melanoma
1.5.7 Hodgkin Lymphoma
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Immune Check Point Inhibitors Market Size
2.2 Immune Check Point Inhibitors Growth Trends by Regions
2.2.1 Immune Check Point Inhibitors Market Size by Regions (2014-2025)
2.2.2 Immune Check Point Inhibitors Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Immune Check Point Inhibitors Market Size by Manufacturers
3.1.1 Global Immune Check Point Inhibitors Revenue by Manufacturers (2014-2019)
3.1.2 Global Immune Check Point Inhibitors Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Immune Check Point Inhibitors Market Concentration Ratio (CR5 and HHI)
3.2 Immune Check Point Inhibitors Key Players Head office and Area Served
3.3 Key Players Immune Check Point Inhibitors Product/Solution/Service
3.4 Date of Enter into Immune Check Point Inhibitors Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Immune Check Point Inhibitors Market Size by Type (2014-2019)
4.2 Global Immune Check Point Inhibitors Market Size by Application (2014-2019)

5 United States
5.1 United States Immune Check Point Inhibitors Market Size (2014-2019)
5.2 Immune Check Point Inhibitors Key Players in United States
5.3 United States Immune Check Point Inhibitors Market Size by Type
5.4 United States Immune Check Point Inhibitors Market Size by Application

6 Europe
6.1 Europe Immune Check Point Inhibitors Market Size (2014-2019)
6.2 Immune Check Point Inhibitors Key Players in Europe
6.3 Europe Immune Check Point Inhibitors Market Size by Type
6.4 Europe Immune Check Point Inhibitors Market Size by Application

7 China
7.1 China Immune Check Point Inhibitors Market Size (2014-2019)
7.2 Immune Check Point Inhibitors Key Players in China
7.3 China Immune Check Point Inhibitors Market Size by Type
7.4 China Immune Check Point Inhibitors Market Size by Application

8 Japan
8.1 Japan Immune Check Point Inhibitors Market Size (2014-2019)
8.2 Immune Check Point Inhibitors Key Players in Japan
8.3 Japan Immune Check Point Inhibitors Market Size by Type
8.4 Japan Immune Check Point Inhibitors Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Immune Check Point Inhibitors Market Size (2014-2019)
9.2 Immune Check Point Inhibitors Key Players in Southeast Asia
9.3 Southeast Asia Immune Check Point Inhibitors Market Size by Type
9.4 Southeast Asia Immune Check Point Inhibitors Market Size by Application

10 India
10.1 India Immune Check Point Inhibitors Market Size (2014-2019)
10.2 Immune Check Point Inhibitors Key Players in India
10.3 India Immune Check Point Inhibitors Market Size by Type
10.4 India Immune Check Point Inhibitors Market Size by Application

11 Central & South America
11.1 Central & South America Immune Check Point Inhibitors Market Size (2014-2019)
11.2 Immune Check Point Inhibitors Key Players in Central & South America
11.3 Central & South America Immune Check Point Inhibitors Market Size by Type
11.4 Central & South America Immune Check Point Inhibitors Market Size by Application

12 International Players Profiles
12.1 Bristol-Myers Squibb Company
12.1.1 Bristol-Myers Squibb Company Company Details
12.1.2 Company Description and Business Overview
12.1.3 Immune Check Point Inhibitors Introduction
12.1.4 Bristol-Myers Squibb Company Revenue in Immune Check Point Inhibitors Business (2014-2019)
12.1.5 Bristol-Myers Squibb Company Recent Development
12.2 AstraZeneca plc
12.2.1 AstraZeneca plc Company Details
12.2.2 Company Description and Business Overview
12.2.3 Immune Check Point Inhibitors Introduction
12.2.4 AstraZeneca plc Revenue in Immune Check Point Inhibitors Business (2014-2019)
12.2.5 AstraZeneca plc Recent Development
12.3 Merck & Co
12.3.1 Merck & Co Company Details
12.3.2 Company Description and Business Overview
12.3.3 Immune Check Point Inhibitors Introduction
12.3.4 Merck & Co Revenue in Immune Check Point Inhibitors Business (2014-2019)
12.3.5 Merck & Co Recent Development
12.4 Pfizer, Inc
12.4.1 Pfizer, Inc Company Details
12.4.2 Company Description and Business Overview
12.4.3 Immune Check Point Inhibitors Introduction
12.4.4 Pfizer, Inc Revenue in Immune Check Point Inhibitors Business (2014-2019)
12.4.5 Pfizer, Inc Recent Development
12.5 F. Hoffmann-La Roche Ltd
12.5.1 F. Hoffmann-La Roche Ltd Company Details
12.5.2 Company Description and Business Overview
12.5.3 Immune Check Point Inhibitors Introduction
12.5.4 F. Hoffmann-La Roche Ltd Revenue in Immune Check Point Inhibitors Business (2014-2019)
12.5.5 F. Hoffmann-La Roche Ltd Recent Development
12.6 Incyte Corporation
12.6.1 Incyte Corporation Company Details
12.6.2 Company Description and Business Overview
12.6.3 Immune Check Point Inhibitors Introduction
12.6.4 Incyte Corporation Revenue in Immune Check Point Inhibitors Business (2014-2019)
12.6.5 Incyte Corporation Recent Development
12.7 NewLink Genetics Corporation
12.7.1 NewLink Genetics Corporation Company Details
12.7.2 Company Description and Business Overview
12.7.3 Immune Check Point Inhibitors Introduction
12.7.4 NewLink Genetics Corporation Revenue in Immune Check Point Inhibitors Business (2014-2019)
12.7.5 NewLink Genetics Corporation Recent Development
12.8 Celldex Therapeutics, Inc
12.8.1 Celldex Therapeutics, Inc Company Details
12.8.2 Company Description and Business Overview
12.8.3 Immune Check Point Inhibitors Introduction
12.8.4 Celldex Therapeutics, Inc Revenue in Immune Check Point Inhibitors Business (2014-2019)
12.8.5 Celldex Therapeutics, Inc Recent Development
12.9 GlaxoSmithKline plc
12.9.1 GlaxoSmithKline plc Company Details
12.9.2 Company Description and Business Overview
12.9.3 Immune Check Point Inhibitors Introduction
12.9.4 GlaxoSmithKline plc Revenue in Immune Check Point Inhibitors Business (2014-2019)
12.9.5 GlaxoSmithKline plc Recent Development
12.10 Seattle Genetics, Inc.
12.10.1 Seattle Genetics, Inc. Company Details
12.10.2 Company Description and Business Overview
12.10.3 Immune Check Point Inhibitors Introduction
12.10.4 Seattle Genetics, Inc. Revenue in Immune Check Point Inhibitors Business (2014-2019)
12.10.5 Seattle Genetics, Inc. Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details